OpGen Long - Possible FDA approval soon

19 févr. 2021

OpGen has gone through a complete accumulation cycle in anticipation of FDA approval for their AMR gene panel. During the last few days of broad market pull back, we see above average volume the downside holding support at $2.80 - $2.90. RSI on the 1HR is approaching oversold. SP has fallen through 50EMA we could possibly see a correction back to uptrend support. 1HR resistance around $3.20 $3.50 $4.00 $4.50 $4.80

Recent Corporate Overview published on 2/16/21

Google - "wyckoff accumulation schematic 1" for more information on accumulation cycle

21 févr. 2021

Transaction en cours

Current average $2.937

Point and Figure chart has bullish price objective of $6.25

2 mars 2021

Note

Recent news
3/1 - receives regulatory approval of the Curetis Unyvero System as an in vitro diagnostics ((IVD)) instrument system in China.
3/2 - Analysts raise price target to $7.00

10 mars 2021

Note

Posted update in comments by accident. Also to add, 3.1M new warrants issued to the previous holder at an exercise price of $3.56